Chimeric receptors with 4-1bb stimulatory signaling domain

a chimeric receptor and stimulatory signaling technology, applied in the field of chimeric cell membrane receptors, can solve the problems of insufficient engagement of the t-cell receptor (tcr) alone to induce persistent activation of resting naive or memory t cells, failure to activate cells, and state of non-responsiveness

Inactive Publication Date: 2013-10-10
ST JUDE CHILDRENS RES HOSPITAL INC
View PDF0 Cites 176 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028]In another embodiment, a method of providing an anti-tumor immunity in a mammal is provided, the method comprising administering to the mammal an effective amount of a cell genetically modified to express an anti-CD19 chimeric rec

Problems solved by technology

For T-cells, engagement of the T-cell receptor (TCR) alone is not sufficient to induce persistent activation of resting naive or memory T cells.
More importantly, engagement of the TCR in the absence of the co-stimulatory signal results in a state of non-responsiveness, called anergy.
Anergic cells fail to become activated upon subsequent stimulation through the TCR, even in the pr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric receptors with 4-1bb stimulatory signaling domain
  • Chimeric receptors with 4-1bb stimulatory signaling domain

Examples

Experimental program
Comparison scheme
Effect test

example 1

9.1 Example 1

Introduction

[0101]In approximately 20% of children and 65% of adults with acute lymphoblastic leukemia (ALL), drug-resistant leukemic cells survive intensive chemotherapy and cause disease recurrence. [Pui C H et al, Childhood acute lymphoblastic leukemia—Current status and future perspectives. Lancet Oncology 2:597-607 (2001); Verma A, Stock W. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 13:14-20T (2001)] lymphocyte-based cell therapy should bypass cellular mechanisms of drug resistance. Its potential clinical value for leukemia is demonstrated by the association between T-cell-mediated graft-versus-host disease (GvHD) and delay or suppression of leukemia recurrence after allogeneic stem cell transplantation. [Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 4:687-698 (1990); Porter D L, Antin J H. The graft-versus-leukemia effect...

example 2

9.2 Example 2

[0139]T lymphocytes transduced with anti-CD19 chimeric receptors have remarkable anti-ALL capacity in vitro and in vivo, suggesting the clinical testing of receptor-modified autologous T cells in patients with persistent minimal residual disease. However, the use of allogeneic receptor-modified T lymphocytes after hematopoietic cell transplantation (HCT) might carry the risk of severe graft-versus-host disease (GvHD). In this setting, the use of CD3-negative natural killer (NK) cells is attractive because they should not cause GvHD.

[0140]Spontaneous cytotoxicity of NK cells against ALL is weak, if measurable at all. To test whether anti-CD 19 chimeric receptors could enhance it, we developed methods to specifically expand human primary NK cells and induce high levels of receptor expression. Specific NK cell expansion has been problematic to achieve with established methods which favor CD3+ T cell expansion. Even after T-cell depletion, residual T cells typically become ...

example 3

9.3 Example 3

Artificial Antigen Producing Cells (APCs) Pave The Way For Clinical Application By Potent Primary In Vitro Induction

Materials And Methods

Cells

[0147]The CD 19 human B-lineage ALL cell lines RS4;11, OP-1, 380, 697, and KOPN57bi; the T-cell line GEM-C7; and the myeloid cell lines K562 and U-937 were available in our laboratory. Cells were maintained in RPMI-1640 (Gibco, Grand Island, N.Y.) supplemented with 10% fetal calf serum (FCS; BioWhittaker, Walkersville, Md.) and antibiotics.

[0148]Primary leukemia cells were obtained with appropriate informed consent and Institutional Review Board (M) approval from nine patients with B-lineage ALL; from four of these patients, we also studied (with IRB approval) cryopreserved peripheral blood samples obtained during clinical remission. An unequivocal diagnosis of B-lineage ALL was established by morphologic, cytochemical, and immunophenotypic criteria; in each case, more than 95% of the cells were positive for CD19. Peripheral blood...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Nucleic acid sequenceaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

Description

2. CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 13 / 761,917, filed on Feb. 7, 2013, which is a divisional application of U.S. patent application Ser. No. 13 / 548,148, filed on Jul. 12, 2012, which is a continuation of U.S. application Ser. No. 13 / 244,981, filed on Sep. 26, 2011, which is a continuation of U.S. patent application Ser. No. 12 / 206,204, filed on Sep. 8, 2008 (granted as U.S. Pat. No. 8,026,097), which is a continuation of U.S. patent application Ser. No. 11 / 074,525, filed on Mar. 8, 2005 (granted as U.S. Pat. No. 7,435,596), which is a continuation-in-part of U.S. patent application Ser. No. 10 / 981,352, filed on Nov. 4, 2004 (abandoned), which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 517,507, filed on Nov. 5, 2003, each of which is incorporated herein by reference in its entirety.1. GOVERNMENT INTEREST[0002]This invention was made in part with U.S. Government support under...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28
CPCC07K16/2866C07K2319/30C12N5/0646C12N2502/99C07K16/2896C07K2319/00C12N2501/2302C12N2501/2315C12N2501/599C12N2510/00A61K39/0011C07K14/7051C07K14/70517C07K14/70578C07K16/2803C07K2317/622C07K2319/02C07K2319/03C07K2317/569C07K16/2878A61K2039/5156A61K2039/5158
Inventor CAMPANA, DARIOIMAI, CHIHAYA
Owner ST JUDE CHILDRENS RES HOSPITAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap